公开(公告)号：US20140378540A1

公开(公告)日：2014-12-25

申请号：US14344628

申请日：2012-09-12

申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Gurmeet Kaur Nanda ,  Sastry V. R. S Thungathurthi ,  Nishan Singh ,  Sudhir Kumar Sharma

发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Gurmeet Kaur Nanda ,  Sastry V. R. S Thungathurthi ,  Nishan Singh ,  Sudhir Kumar Sharma

IPC分类号： C07D309/10 ,  C07D493/08

CPC分类号： C07D309/10 ,  C07D493/08 ,  C07H7/04

摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

摘要翻译： 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I的新化合物和治疗或预防一种或多种可通过抑制葡萄糖转运蛋白-2（SGLT-2）调节或归一化的病症或疾病的药物组合物。

公开(公告)号：US20140228303A1

公开(公告)日：2014-08-14

申请号：US14126268

申请日：2012-06-13

申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Gurmeet Kaur Nanda ,  Sastry V. R. S Thungathurthi ,  Nishan Singh ,  Sudhir Kumar Sharma

发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Gurmeet Kaur Nanda ,  Sastry V. R. S Thungathurthi ,  Nishan Singh ,  Sudhir Kumar Sharma

IPC分类号： A61K31/7048 ,  A61K31/70 ,  C07H19/01 ,  C07H7/04

CPC分类号： A61K31/7048 ,  A61K31/70 ,  C07D309/10 ,  C07D401/04 ,  C07D493/08 ,  C07H7/04 ,  C07H9/04 ,  C07H13/04 ,  C07H13/12 ,  C07H15/04 ,  C07H19/01

摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).